Johnson & Johnson's Janssen, which has struggled to maintain ready supplies of its ovarian cancer treatment Doxil, has released a new lot of the popular drug. The injectable cancer med was produced through an "alternative manufacturing approach" in which the now-closed Ben Venue plant in Ohio made the bulk product and another manufacturer finished it off.
written on 24.03.2014